OncoLink Cancer Treatment and Resources

DES Exposure and Gynecologic Cancer

John Han-Chih Chang, MD and Kenneth Blank, MD
Last Modified: November 1, 2001

Question
Dear OncoLink "Ask the Experts,"
I found your information on cervical changes and treatment options for abnormal pap tests very informative. In 1996 I underwent a LEEP procedure for the treatment of mild dysplasia and squamous intra-epithelial lesions. The first PAP (3 months) after the procedure, was not entirely normal, and the test was repeated 3 months later at which time it was normal. The next PAP, 11 months later showed the same atypical cells as had been evident before. My physician has recommended I undergo a cone biopsy at this time. Careful monitoring of the PAP will continue after this procedure. He feels that if smears continue to be abnormal I ought to consider a hysterectomy. I am a DES exposed daughter, and know that these changes could be the result of the exposure, however I have not been able to find any references to this connection in the literature or on your pages or anywhere on the Internet. Do you know of any studies or medical literature that discusses the connection between DES exposure and reactive changes? I would be very interested in hearing about other women with a similar history and management of cell changes.  
Thank you,
VF


Answer
John Han-Chih Chang, MD and Kenneth Blank, MD, Editorial Assistants for Oncolink, respond:

Dear VF,
In the 1970's, it was discovered that diethylstilbestrol (DES) was related to an increased incidence of clear-cell adenocarcinoma of the vagina and cervix. The incidence of this is still very low (less than 2 in 1000), but represents a real risk. Approximately, half of all clear cell carcinomas of the cervix and vagina have a history of the patient being exposed in utero to DES. The median age at which these cancers are diagnosed is in the early 20's. The risk is greatest when the mother was given DES during the first trimester. The incidence of intraepithelial neoplasia was double the rate in the normal non-exposed population.

Your management has been very appropriate for what you have described. There is not significant literature discussing DES and these reactive changes, but there have definitely been references to the increased risk for the abnormal PAP.

Please refer to the following OncoLink pages regarding general information on gynecological cancers.

OncoLink I wish u knew...

Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS